The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States
Top Cited Papers
Open Access
- 15 December 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (12), 2257-2264
- https://doi.org/10.1093/cid/ciab079
Abstract
Background. Global vaccine development efforts have been accelerated in response to the devastating coronavirus disease 2019 (COVID-19) pandemic. We evaluated the impact of a 2-dose COVID-19 vaccination campaign on reducing incidence, hospitalizations, and deaths in the United States. Methods. We developed an agent-based model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and parameterized it with US demographics and age-specific COVID-19 outcomes. Healthcare workers and high-risk individuals were prioritized for vaccination, whereas children under 18 years of age were not vaccinated. We considered a vaccine efficacy of 95% against disease following 2 doses administered 21 days apart achieving 40% vaccine coverage of the overall population within 284 days. We varied vaccine efficacy against infection and specified 10% preexisting population immunity for the base-case scenario. The model was calibrated to an effective reproduction number of 1.2, accounting for current nonpharmaceutical interventions in the United States. Results. Vaccination reduced the overall attack rate to 4.6% (95% credible interval [CrI]: 4.3%-5.0%) from 9.0% (95% CrI: 8.4%-9.4%) without vaccination, over 300 days. The highest relative reduction (54%-62%) was observed among individuals aged 65 and older. Vaccination markedly reduced adverse outcomes, with non-intensive care unit (ICU) hospitalizations, ICU hospitalizations, and deaths decreasing by 63.5% (95% CrI: 60.3%-66.7%), 65.6% (95% CrI: 62.2%-68.6%), and 69.3% (95% CrI: 65.5%-73.1%), respectively, across the same period. Conclusions. Our results indicate that vaccination can have a substantial impact on mitigating COVID-19 outbreaks, even with limited protection against infection. However, continued compliance with nonpharmaceutical interventions is essential to achieve this impact.Funding Information
- Canadian Institutes of Health Research (OV4 – 170643)
- São Paulo Research Foundation (18/24811-1)
- National Institutes of Health (1RO1AI151176-01, 1K01AI141576-01)
- National Science Foundation (RAPID 2027755, CCF-1918784)
This publication has 35 references indexed in Scilit:
- Novel Coronavirus (COVID-19) Epidemic: What Are the Risks for Older Patients?Journal of the American Geriatrics Society, 2020
- Presumed Asymptomatic Carrier Transmission of COVID-19JAMA, 2020
- The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in ChinaJournal of Travel Medicine, 2020
- Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysisInternational Journal of Infectious Diseases, 2020
- Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020Eurosurveillance, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine ProgramsJournal of Virology, 2019
- The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly PeopleThe Journal of Infectious Diseases, 2017
- Ageing and the epidemiology of multimorbidityEuropean Respiratory Journal, 2014
- Social Contacts and Mixing Patterns Relevant to the Spread of Infectious DiseasesPLoS Medicine, 2008